Tag Archives: LXRX

Stifel Nicolaus Reiterates a Buy Rating on Lexicon Pharmaceuticals

In a report released yesterday, Stephen Willey from Stifel Nicolaus reiterated a Buy rating on Lexicon Pharmaceuticals (NASDAQ: LXRX), with a price target of $23. The company’s shares closed yesterday at $11.43. According to TipRanks.com, Willey is a 5-star analyst

Needham Keeps a Hold Rating on Lexicon Pharmaceuticals

In a report released today, Alan Carr from Needham maintained a Hold rating on Lexicon Pharmaceuticals (NASDAQ: LXRX). The company’s shares opened today at $12.58. Carr wrote: “Lexicon reported 2Q18 U.S. Xermelo sales of $6.0M, below our $7.0M and consensus

Lexicon Pharmaceuticals Receives a Hold from Needham

In a report released today, Alan Carr from Needham maintained a Hold rating on Lexicon Pharmaceuticals (NASDAQ: LXRX). The company’s shares opened today at $13.53. Carr noted: “Lexicon presented additional data from sotagliflozin Phase 3 program in at ADA mtg

Wedbush Keeps Their Buy Rating on Lexicon Pharmaceuticals

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Lexicon Pharmaceuticals (NASDAQ: LXRX), with a price target of $42. The company’s shares opened today at $13.02. According to TipRanks.com, Moussatos is a 4-star analyst with

Analysts Are Bullish on These Healthcare Stocks: LXRX, BYSI

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Lexicon Pharmaceuticals (NASDAQ: LXRX) and Beyondspring Inc (NASDAQ: BYSI) with bullish sentiments. Lexicon Pharmaceuticals (NASDAQ: LXRX) In a report released today, Liana

Needham Thinks Lexicon Pharmaceuticals’ Stock is Going to Recover

In a report issued on September 13, Alan Carr from Needham reiterated a Buy rating on Lexicon Pharmaceuticals (NASDAQ: LXRX), with a price target of $21. The company’s shares closed on Friday at $12.37, close to its 52-week low of